Korro Bio, Inc.

NasdaqCM KRRO

Korro Bio, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD -13.60

Korro Bio, Inc. Free Cash Flow Per Share is USD -13.60 for the Trailing 12 Months (TTM) ending September 30, 2024, a -53.19% change year over year. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.
  • Korro Bio, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -8.88, a 73.20% change year over year.
  • Korro Bio, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -33.12, a 71.82% change year over year.
  • Korro Bio, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -117.52, a -17.81% change year over year.
  • Korro Bio, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -99.75.
Key data
Date Free Cash Flow Per Share Return on Assets (ROA) Return on Equity (ROE) Return on Capital Employed (ROCE)
Market news
SV Wall Street
NasdaqCM: KRRO

Korro Bio, Inc.

CEO Mr. Ram Aiyar MBA, Ph.D.
IPO Date Oct. 3, 2019
Location United States
Headquarters One Kendall Square
Employees 101
Sector Healthcare
Industries
Biotechnology Pharmaceuticals
Description

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

StockViz Staff

February 4, 2025

Any question? Send us an email